Onward received grants from the Michael J. Fox Foundation ($ 1m) and the US Department of Defense ($ 1.5m) to study its ARC-IM system in Parkinson’s disease. With these grants, the company aims to set up clinical feasibility studies to assess both mobility and blood pressure instability in Parkinson’s patients. The move into Parkinson’s follows an earlier case study and could become a second pillar for Onward if positive results can be confirmed.
Dave Marver, CEO, Onward Medical.
